Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49 Though the ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had ...

Vaccination campaigns have nearly eradicated some of the most deadly and transmissible diseases. In a rising tide of vaccine ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

A passion for learning took her from apartheid South Africa to a beer brewery to becoming a healthcare consultant, all before ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

These five well-known dividend stocks were beaten down in the recent selling but will remain attractive long after the tariff ...

UBS analyst Trung Huynh lowered the firm’s price target on Pfizer (PFE) to $24 from $28 and keeps a Neutral rating on the shares. The firm says ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.